Navigation Links
Creabilis Appoints George F. Horner III as its Chairman
Date:9/15/2010

orner also worked for Ligand Pharmaceuticals following a successful career at Abbott Laboratories where his final position was as President of the company's business in Canada. Mr Horner has also acted as an adviser to a number of specialist life science investors in recent years.

Commenting on his new role, George F. Horner III said: "I am excited to be joining Creabilis given its potential to deliver the genuine innovation that is needed to transform the dermatology market. I have been attracted to this opportunity by the Company's rich pipeline of clinical and pre-clinical drug candidates focussed on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its unique technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders."

Graziano Seghezzi, Partner at Sofinnova, said: "We are delighted to have someone with George's track record in building successful high-value biotech businesses as Chairman of Creabilis. I am sure his strategic and operational experience will be vital as we look to progress the Company's exciting pipeline, build the management team and develop our LSE (Low Systemic Exposure) technology, so that Creabilis can generate new prescription medicines that will make a significant improvement to the treatment of skin diseases."

About Creabilis SA

Creabilis is a clinical stage European biotechnology company creating highly innovative new drugs to tackle unmet medical needs in serious dermatological diseases. Bringing together world class drug development capabilities and a rich scientific heritage, Creabilis is uniquely positioned to transform the treatment of skin diseases.

Creabilis' lead product is CT327, a novel topically applied TrkA kinase inhibitor developed using the Company's LSE (Low Systemic Exposure) technology. LSE technology creates new chemical
'/>"/>

SOURCE Creabilis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Elsevier Appoints Suzanne BeDell as Managing Director, Science and Technology (S&T) Books
2. ZS Associates Appoints Pharmaceutical Industry Veteran to Serve the Firms Growing Client Base in Germany
3. BioStorage Technologies Appoints New Global Director of Supply Chain
4. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
5. Pevion Biotech Appoints New CEO and Secures CHF 10 Million Financing
6. Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain
7. PharmaVentures Appoints Paul Phull as Senior Director
8. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
9. Jennerex Appoints Lara Longpre to Chief Operating Officer
10. Regenicin Appoints Amgen Co-founder Dr. Joseph Rubinfeld to Board of Directors
11. Fluidnet Corporation Appoints Benjamin E. Bulkley President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015 Ultra Clean ... Intuitive Surgical, the manufacturer of da Vinci® ... Cleaning System. This approval reflects the unit,s ability ... currently in place for the sterile processing industry. ... reprocessing robotic surgical instruments for re-use. ...
(Date:3/6/2015)... 2015  The German Court of Appeal has ruled that ... regimen patent for Alimta® (pemetrexed disodium) would not be infringed ... salt form of pemetrexed in Germany ... The German Court ruled in favor of the generic ... Actavis. This decision vacated the prior decision of the Regional ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 3TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows ... and Pulmonary,Embolism Compared with Enoxaparin with Similarly ... - Late-breaking Phase III clinical trial,data presented ... Thrombosis,and Haemostasis (ISTH) Congress demonstrate that once-daily,rivaroxaban ...
... Massachusetts, July 08, 2007 /PRNewswire/ -- , ... to Urgently,Implement Hospital-Wide Strategies to Optimize VTE ... Provide Appropriate,prophylaxis to Prevent VTE , Venous ... and most of these at-risk patients are ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
(Date:3/6/2015)... (PRWEB) March 06, 2015 As the ... healthcare services programs, the organization has hired two new ... Ph.D. They will report to Grace Pavlath, Ph.D, ... President and Scientific Program Director, and together will lead ... to treatments and cures for various types of neuromuscular ...
(Date:3/6/2015)... 2015 “On Tap” takes the audience on ... stage, to the silver screen and to modern day rhythm ... numbers and their famous eye-high kicks! Producers, directors and choreographers ... of tap dancing in this robust show, showcasing one of ... United States. , “On Tap” is proud to host ...
(Date:3/6/2015)... 06, 2015 US Sports Football Camps ... camps – two non-contact specialty camps and one contact ... Perfect Performance Training, located at Bowie State University and ... position specific skills, speed and strength of football athletes. ... University with Marvin Graves, former quarterback in the Canadian ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 At ... company, announced today the launch of its powerful, ... on healthy and sustainable products at any retailer ... is exhibiting at Expo West Booth 6054. ... by gluten-free, Kosher, non-GMO, organic, Paleo, and vegan, ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3
... , TUESDAY, Feb. 8 (HealthDay News) -- Heavy drinking ... and is associated with long-term alcohol-related problems, researchers warn. ... drinking among older teens not only prevents immediate harm, ... the study authors pointed out. The researchers reviewed ...
... slightly higher in the offspring of male cancer survivors ... cancer, according to a study published online February 8th ... The increasing number of male cancer survivors ... their offspring. Although previous studies on children conceived naturally ...
... -- Researchers at the University at Buffalo have devised ... these medically important molecules from losing their shape and ... help speed the development of peptide-based drugs against diseases ... are simpler than existing techniques, one of which employs ...
... (HealthDay News) -- People whose genetic make-up produces lower levels ... at increased risk for major depression, says a new study. ... down after experiencing stressful events. This study found that ... cause them to produce lower levels of NPY have stronger ...
... (HealthDay News) -- Babies who are exposed to HIV at ... levels of antibodies to diseases such as whooping cough, tetanus ... samples from 104 HIV-infected and uninfected South African women and ... of the infants at 16 weeks of age. The samples ...
... beneath the surface, a team of researchers from the ... three South Korean institutions have identified two distinct neuronal ... treat a variety of skin diseases. One pathway produces ... a side effect. The findings, published in this ...
Cached Medicine News:Health News:Male cancer survivor offspring slightly higher risk of congenital birth abnormalities 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:Study Links Brain Molecule to Risk of Major Depression 2Health News:Mom's HIV May Lower Baby's Immunity to Other Diseases 2Health News:The hitch in the drug? The itch in the drug 2
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: